Human African trypanosomiasis prevention, treatment and control costs: A systematic review

Joseph Keating^{*a,b}, Joshua O. Yukich^{a,b}, C. Simone Sutherland^{c,d} Geordie Woods^e & Fabrizio
Tediosi^{c,d,f}

^a Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, 1440 Canal Street, Suite 2200, New Orleans, LA, 70112, Email: jkeating@tulane.edu and jyukich@tulane.edu; ^b Department of Tropical Medicine, Tulane University School of Public Health and Tropical Medicine, 1440 Canal Street, Suite 2309, New Orleans, LA, 70112; ^c Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Socinstrasse 57, 4002, Basel; ^d University of Basel, Switzerland, Email: simone.sutherland@unibas.ch and fabrizio.tediosi@unibas.ch; ^e Sightsavers, 35 Perry Mount Road, Haywards Heath, West Sussex RH16 3BW England, Email: gwoods@sightsavers.org; ^f Centre for Research on Health and Social Care Management (CERGAS), Università Bocconi, Milan, Italy.

*** Corresponding Author:** Dr. Joseph Keating, Department of Tropical Medicine and the Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, 1440 Canal Street, Suite 2200, New Orleans, LA, 70112; Tel: 504.988.1348; Fax: 504.988.3653; email: jkeating@tulane.edu

23	Key Words
24	Trypanosomiasis
25	Sleeping sickness
26	Cost
27	Prevention
28	Treatment
29	Control
30	

Abstract

The control and eventual elimination of human African trypanosomiasis (HAT) requires the expansion of current control and surveillance activities. A systematic review of the published literature on the costs of HAT prevention, treatment, and control, in addition to the economic burden, was conducted. All studies that contained primary or secondary data on costs of prevention, treatment and control were considered, resulting in the inclusion of 42 papers. The geographically focal nature of the disease and a lack of standardization in the cost data limit the usefulness of the available information for making generalizations across diverse settings. More recent information on the costs of treatment and control interventions for HAT is needed to provide accurate information for analyses and planning. The cost information contained herein can be used to inform rational decision making in control and elimination programs, and to assess potential synergies with existing vector-borne disease control programs, but programs would benefit significantly from new cost data collection.

1. Introduction

Human African trypanosomiasis (HAT), which is also known as sleeping sickness, is caused by an infection with either of two parasites: *Trypanosoma brucei rhodesiense* or *Trypanosoma brucei gambiense*. Both types are transmitted by different tsetse fly species. They are microscopically indistinguishable, but occur in separate areas of Sub-Saharan Africa (SSA). A total of 37 countries between 14° N and 20° S latitude and covering 1.55 million km² have reported cases (Simarro et al 2012a). *T.b. gambiense* occurs in west and central Africa, while *T.b. rhodesiense* is endemic in eastern and southern Africa. There is no overlap between the endemic areas with Uganda being the only country endemic for both forms, albeit in different areas of the country (Burri 2008). An estimated 70 million people (Simarro et al 2012a) and about 50 million head of cattle are at risk of trypanosomiasis infection (Fevre et al 2008, Kristjanson et al 1999). The main reservoir host for *T.b. gambiense* is humans, while cattle or wild bovids serve as the main reservoir host for *T.b. rhodesiense*. Animal to human, animal to animal, and human to human transmission all occur with *T.b. rhodesiense*. Transmission varies as a function of vector density and biting behavior. A total of 7,216 HAT cases for both *T.b. gambiense* and *T.b. rhodesiense* were reported in 2012 (WHO 2013) and the World Health Organization (WHO) estimates the number of actual infections to be around 20,000 (WHO 2013). In 2014, WHO approved a declaration to target *gambiense* HAT elimination (Holmes 2014) and one to target *rhodesiense* HAT (WHO 2014a).

A previous review of the available economic evaluations for HAT (Sutherland et al 2015) demonstrates that although cost-effectiveness has been assessed previously for control of the disease little is known about the cost-effectiveness of strategies targeting elimination. Funding and support for HAT declined from the 1970s through the 1990s, contributing to the resurgence

of the disease in the late 1990s (Smith et al 1998); however, since the WHO's roadmap to NTD control and elimination was published in 2012 (WHO 2012), there is a renewed commitment from global stakeholders to achieve HAT elimination by 2020 (Zhang et al 2010; London Declaration to Combat NTDs, 2013, WHO 2012, BMGF 2015). This requires that the total cost of potential strategies for elimination along with current and emerging technologies (Steinman et al 2015) are accurately estimated to ensure that funding is sustained throughout the elimination process.

The purpose of this paper is to summarize the available information on costs for HAT prevention, treatment, and control to serve as a reference for future economic evaluations and national budgeting endeavors. The paper begins with a brief description of the treatment, prevention and control strategies for the disease to provide relevant contextual information and some potential interventions for elimination. It then presents a systematic review of the published literature that included primary and secondary data on costs, indirect costs and economic burden related to HAT programs. The paper concludes with a discussion on priority areas of economic data collection for elimination strategy development.

1.1 Prevention, treatment, control of HAT

In general, the prevention of HAT includes reducing bites from tsetse flies, early diagnosis and treatment of cases. While individual protection against bites may be useful in some instances, the fly can penetrate light weight clothing and repellants are not common in many endemic areas. Thus community level vector control and screen and treat programs, which involve the detection of human cases for subsequent treatment, are typically employed together. Several techniques are recommended for the control of tsetse fly populations: sequential aerial

insecticide spraying to target adult flies during the first spray and tsetse flies as they emerge from pupal stages in the ground during subsequent sprays; ground spraying to target pupae and resting flies; the use of odor-baited or visual-baited (*e.g.* black or blue cloth) insecticide treated traps and targets; sterile insect release; and insecticide treatment of cattle (ICT) (Welburn et al 2009). A total of 13 Sleeping Sickness National Control Programs are developing vector control activities (out of 24 countries reporting HAT cases) (Franco et al 2014), although in some countries institutions other than national control programs are also engaged in vector control activities.

Few drugs are available for the treatment of trypanosome infections. Pentamidine and suramin are the main treatments for 1st stage *T.b. gambiense* and *T.b. rhodesiense*, respectively (WHO 2013). The 2nd stage of *T.b. rhodesiense* is treated with the organoarsenical compound melarsoprol (WHO 2013), which is associated with severe adverse reactions, mainly arsenical encephalopathy, occurring in 10% of the patients and frequently fatal (10-70% mortality) (Pepin & Milord 1994, Burri 2008). Nifurtomix-eflornithine combination therapy (NECT) is currently the treatment of choice for stage 2 *T.b. gambiense* and is listed on the WHO's Model List of Essential Medicines (http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1). It involves an in-hospital treatment combining intravenous infusions of eflornithine with oral treatments of nifurtimox (WHO 2013). An alternative treatment for *T.b. gambiense* is eflornithine monotherapy which must be given in a high dose for an extended duration and is recommended when NECT is unavailable, but is not as well tolerated as NECT (WHO 2013). Melarsoprol is used when patients treated with NECT relapse (WHO 2013). New treatments are currently being developed: fexinidazole is a 10-day oral medication (DNDi 2014) that could potentially be used even if health systems lack the infrastructure or resources to administer NECT. Another potential treatment option is a single-dose oxaborole compound (DNDi 2014), allowing patients to be

potentially treated locally and thus avoiding travel to specialized treatment centers that are often far from home. Active and passive case finding are crucial to identify and treat cases to curb transmission.

2. Methods

A systematic electronic search of literature published in the English and French language was conducted using Pubmed (MEDLINE), EMBASE, and JSTOR databases in 2013. The following search terms were used: trypanosomiasis, African sleeping sickness, and (economics, cost, cost-effectiveness, cost-benefit, economic, internal rate of return, eradication, elimination, health systems, vertical, integration). All results were initially reviewed for relevance based on a review of the title and abstract; the selected publications were then further reviewed for relevance using the full text. The bibliographies of identified references were also searched, as well as the grey literature using Google and Open Content search engines.

All papers with primary or secondary data on economic burden, costs of interventions, or health system implications of control and elimination programs were selected for more detailed review. All papers with primary data on costs of any topic related to treatment, prevention, control, indirect costs and economic burden were included. Figure 1 illustrates the incremental results of the search. A total of 960 papers were identified as potentially relevant; a total of 42 papers met the criteria. All cost data were adjusted to USD in the year of the initial study (if the researchers had not already done so) if this information was available using historical exchange rate data from the Oanda currency converter (<http://www.oanda.com/currency/converter/>). If information on the year of the study was not available, the year of the publication was used as a basis for adjustment. The availability of historical exchange rates varies across countries; as

such, studies identified with foreign cost data prior to historical exchange rate availability were first converted to USD using the first year exchange rate data were available. All costs were then adjusted to 2012 USD using the U.S. Gross Domestic Product Deflator series from the U.S. Bureau of Economic Analysis (<http://www.bea.gov>).

3. Results

3.1 Prevention: vector control costs

3.1.1 Sequential Aerosol Techniques

Sequential aerosol techniques (SAT) refer to the spraying of targeted areas with a non-residual insecticide from a fixed wing of an airplane at set intervals. The first spray is designed to kill adults, with subsequent sprays targeted at killing young adult tsetse as they emerge from puparia buried in the ground but before they deposit larvae. Few cost estimates of SAT were identified. Shaw and others used data collected from SAT activities in Botswana to develop a cost model and hypothetical budget for Uganda; SAT in both settings were estimated to cost USD 410.56 per km², with the bulk of costs incurred due to flying time of the aircraft and type of insecticide used (Shaw et al 2007, Shaw et al 2013).

While relatively few peer reviewed published studies of SAT were identified through electronic searches, several secondary sources of historical cost data from African locations were noted in Allsopp and Hursey (2004). Botswana and Zambia (1973-1980) reported USD 231.95 per Km² of Endosulfan and pyrethroids; Nigeria (1977) reported USD 890.62 per Km² of Endosulfan (Lee et al 1982); Cote d'Ivoire (1979) reported USD 617.00 per application of Endosulfan (Lee et al 1982); and Zambia (1968-1978) reported a range of USD 827.38 – 1,103.19 per Km², although the insecticide used was not mentioned (Evinson and Kathuria 1984, Allsopp and Hursey 2004). One study in West Africa also reported the cost of non-SAT from a

helicopter to be between USD 1.55 – 2.75 per hectare, assuming 2,000 – 3,500 hectares covered per application, respectively (Brandl 1988a). The historical literature also suggests that the cost per area covered is inversely proportional to the total area sprayed, because fixed and capital costs for SAT do not increase proportionally with the total area covered. Additionally it is noted that elimination of tsetse from targeted areas requires high dosages of insecticide sprayed five times at narrow spray band widths, while SAT or other aerial insecticide application targeted only at control of tsetse could relax all these parameters and perhaps reduce cost per km² by 30-50% (Allsopp and Hursey 2004). Across several ecologically distinct settings, SAT in general is thought to cost between USD 285.81 – 628.79 per Km² (Cattand et al 2006).

3.1.2 Sterile Insect Techniques

Sterile insect technique (SIT) refers to mass release of sterile male tsetse flies, which then compete with non-sterile males to mate with females, resulting in adult female flies unable to produce offspring. This method of vector control is generally used in areas where the number of flies is relatively low; as such, it is typically employed following SAT or other vector control strategies that first reduce vector density. Using a 10% discount rate, SIT was estimated to cost USD 840.76 per km² over a ten year period (Shaw et al 2007). In West Africa, the estimated the cost of adding SIT to an existing intervention was USD 970.00/km², although in areas where substantially fewer sterile males would be required, the cost of SIT could fall to USD 303.12-363.75/km² (Feldman 2004) depending on how many sterile males are released per kilometer and the cost of the flight plan employed (Vale and Torr 2005).

3.1.3 Ground Spraying

Ground based spraying of insecticides can be conducted using either pressurized spray pumps or thermal fogging equipment and may be targeted to wide swaths or to specific areas or

habitat believed to be tsetse resting areas. Relatively little literature on the costs of ground spraying was identified, including three studies cited which could not be obtained in hard copy for review, but whose results are summarized from secondary sources. A study during the late 1950's in Kenya reported ground spraying costs at USD 367.26 per km². In Nigeria, from 1955-1969, costs were reported to range between USD 29.74 – 592.84 per km²; and, in Zimbabwe during the early 1980's cost ranged between USD 260.68 – 274.05 per km² (Allsopp and Hursey 2004). One study reported cost between USD 315.00 – 1,574.98 per km² in 1989, although no additional information was provided (Shaw 1989).

3.1.4 Traps and Targets

Traps and targets refer to direct suppression methods that function by trapping flies or by using visual attractants such as large dark colored cloth (targets), which can be treated with insecticide. These tools can be baited with odor based attractants to attract flies from a distance, or modified in various manners and produced in alternate sizes and shapes. Such vector control tools have been deployed for direct tsetse suppression and as a barrier method to prevent invasion/re-invasion of tsetse into specific geographic areas.

Costs first estimated in 1997 have recently been updated, suggesting that targets cost between USD 266.75 and USD 466.81 per km² (Shaw 2004, Barrett 1997). The cost of using targets to produce a linear barrier has been estimated to be USD 2,425.00 per km to establish and USD 1,940 per km per year to maintain (Shaw 2004). The cost of using monopyramidal traps are estimated at USD 31.52 per km², assuming 17 cattle per km² (Shaw 2004). The cost of targets has also been estimated at USD 305.76 per km² in Botswana (McCord et al 2012, Mullins et al 1999), and USD 128.03 when used for control (Allsopp and Hursey 2004, McCord 2012). Traps used for reclamation purposes have been estimated to cost between USD 1.05 and USD

2.05 per hectare per year over a period of 5 to 20 years, when fully discounted (Brandl 1988a). The cost per km² when traps and targets are deployed for elimination purposes ranges from USD 343.14 and USD 880.27 per km², depending on the discount rate and the number of traps deployed per km² (Shaw et al 2007). Other factors influencing trap or target cost include the size and type of trap used, insecticide or odor based attractant used and dosage, as well as the deployment method and density and lifetime of the trap in the field (Shaw et al 2007, Esterhuizen et al 2011).

3.1.5 Insecticide treated cattle (ITC)

In West Africa ITC is mainly limited to control of animal trypanosomiasis (nagana), but in East Africa it has also been shown to help control HAT because cattle serve as an important reservoir for *T.b. rhodesiense*. The costs for ITC vary depending on the scope of application (i.e. whole cattle pour-on vs. leg and belly application only), the density of cattle in the area, and the insecticide chosen. The cost of ITC has been estimated to be USD 164.54 per km² for the full pour-on treatment when there are 15 cattle per km² (Barrett 1997, Budd 1999, Shaw et al 2004). Updated cost estimates from Uganda suggest that the least expensive application is treatment of cattle legs and belly with an α -cypermethrin spray (USD 14.55 per km² assuming 8 cattle per km²) followed by full body α -cypermethrin spray (USD 67.90 per km²) and pour on treatment (USD 218.25 per km²)(Shaw et al 2007). Models restricting the application of insecticide to only the legs and bellies of cattle, where most tsetse bites occur, produced similar cost estimates (Torr and Vale 2007, Vale and Torr 2005). Table 1 presents additional vector control cost information.

3.2 Costs of treatment and hospitalization for HAT

3.2.1 Treatment costs

For treatment of first stage *T.b. gambiense* infection, pentamidine is the WHO recommended drug (WHO 2014b). In Africa, approximately 1% of patients die due to pentamidine, though why pentamidine mortality occurs is not well explored (Burri 2008). No costing studies on the treatment of first stage HAT due to *T.b. gambiense* with pentamidine were identified in the literature search. Costs of pentamidine treatment were estimated by Lutumba (2007) and Shaw and Cattand (2001) to be USD 2.05 per vial and USD 25.61 total drug costs, respectively. Suramin, although effective as a treatment for first stage illness is largely avoided for *T.b. gambiense* infection because of the potential for allergic reactions associated with onchocerciasis co-infection (Burri 2008).

The recommended treatment for first stage *T.b. rhodesiense* infection is suramin administered parenterally over a period lasting up to 30 days (Burri 2008). Record reviews of hospital data combined with past literature were used to estimate the cost of treatment for early and late stage *T.b. rhodesiense* in Urambo district Tanzania; although this study failed to differentiate costs of late stage versus early stage patients, they reported an estimated cost of USD 130.95 per patient, including admission, hospitalization, diagnostic and patient costs. Of this, the patient paid USD 30.31 out of pocket, while the net cost to the health system was estimated to be USD 100.64 (Matemba et al 2010).

The first line second-stage treatment of *T.b. gambiense* is NECT and has been estimated to cost USD 1,550.74 for a kit containing 4 treatments resulting in the cost of USD 387.68 for one treatment. (Simarro 2012b) Alternative treatments such as melarsoprol or eflornithine may be used as well (WHO 2013). Using clinical data from 690 second stage *T.b. gambiense* patients

in Caitxo, Angola, a decision tree model was developed to estimate the total cost per patient treated, including costs of supportive care in addition to adverse events such as arsenical encephalopathy; treatment with melarsoprol was USD 708.03, while treatment per patient with eflornithine was approximately USD 997.14 (Robays et al 2008). Eflornithine was more efficacious in terms of mortality prevention; this translated into improved cost-effectiveness for eflornithine vs. melarsoprol despite the higher cost. Melarsoprol is currently the only drug available for treatment of stage II *T.b rhodesiense* infection. No studies on the costs of treatment for stage II *T.b. rhodesiense* infection were identified; however, as the treatment regimen is expected to be similar to that used for stage II *T.b. gambiense* infection, the costs from the two studies discussed above may be relevant (Robays et al 2008, Politi et al 1995). No specific studies on the costs of encephalopathy as a severe adverse event associated with the administration of melarsoprol were identified; however, the direct costs of management of these complications were estimated in the context of the decision model discussed above to be between USD 23.60 – 59.00 (Robays et al 2008).

The cost of the new treatment options, fexinidazole has been estimated to be less than USD 50 per patient (DNDi 2014 while no estimates have been confirmed for oxaborole. Table 2 lists additional treatment costs identified.

3.2.2 Hospitalization costs

Treatment of HAT generally requires close supervision due to the risks associated with treatment; treatment of late stage disease invariably requires hospitalization. There is little in the literature about specific costs of hospitalization for treatment due to HAT. When including both early and late stage infections, the mean length of a hospital stay has been estimated at 25 days (Matemba et al 2010). In this study the total costs to the health service were estimated to be USD

2.42 per patient per night in the hospital and USD 1.21 per initial diagnosis. A second study in Angola estimated the auxiliary staff cost to be USD 7.43 and USD 17.70 per patient per day for treatment with melarsoprol and eflornithine, respectively; the cost of expatriate staff regardless of which drug was used was estimated to be USD 6.73 (Robays et al 2008). In addition, the cost of nurse time per diem for the administration of melarsoprol and eflornithine is USD 5.90 – 17.70 and USD 5.90 - 23.60, respectively; the cost of an adverse event associated with the administration of melarsoprol is estimated to be USD 44.61 (Robays et al 2008).

3.3 Control costs for HAT

3.3.1 Case detection and surveillance costs

Of the 60 million people estimated to be at risk for HAT, only 3-4 million are under any form of surveillance (Cattand et al 2001). A 2001 paper by Shaw and Cattand builds on a series of previous WHO reports and analytical work on control and surveillance of trypanosomiasis to outline five potential surveillance methods and to estimate their costs and cost-effectiveness using a spreadsheet model (Shaw and Cattand 2001). These include active case detection, which is divided into 1) monovalent surveillance teams looking only for sleeping sickness, 2) polyvalent teams looking for other diseases in addition to HAT, and 3) sampling of community workers to collect blood on filter paper. Passive case detection, which is divided into 4) fixed-post surveillance or traditional surveillance in which patients who cannot be diagnosed with another disease are eventually referred to a HAT treatment center for further testing, or 5) sampling of patients at rural health centers to collect blood on filter paper regardless of the reason for the patients original presentation. Road blocks near health centers have also been used as a form of active case detection. Table 3 summarizes costs associated with case detection and surveillance.

3.3.2 Diagnostic costs

The most frequently used method for diagnosis of *T.b. gambiense* is the card agglutination test for trypanosomiasis (CATT); lumbar puncture is also necessary for determination of cerebrospinal fluid involvement. Controlled lumbar punctures are recommended for late stage West African trypanosomiasis every 6 months for up to 3 years after diagnosis and therapy. In East African trypanosomiasis they should be carried out more frequently (*i.e.* every 3 months during the first year). The cost of CATT is estimated at USD 2.51 per test (Molyneux 2010). Costs associated with diagnostic tests, in addition to new loop-mediated isothermal amplification (LAMP) methodologies are presented in table 2. Some of the treatment and surveillance studies noted above also include the costs of diagnosis of the disease in their total cost estimates (Shaw and Cattland 2001, Robays et al 2008).

3.4 Economic burden

Human and animal trypanosomiasis has been estimated to cause a large economic burden to families and livestock producers in endemic areas. The diseases are thought to be important contributors to rural underdevelopment (Kristjanson et al 1999, Budd 1999, Swallow 2000) . While this review focuses on the human health and economic effects of HAT, *T.b. rhodienesense*, which infects both humans and animals, may also be responsible for a significant economic impact through limitations on land use and livestock rearing due to increased mortality and limited weight gain among infected livestock (Jemal & Hughjones 1995, Jemal et al 1995, Agyemang et al 1991, Agyemang et al 1990, Wilson et al 1986, Kamuanga et al 2001).

Although the economic impact of trypanosomiasis has been addressed in recent years, much of this research has been focused on animal trypanosomiasis (nagana or other variants). While HAT is related and overlapping geographically with transmission of animal

trypanosomiasis, interactions between the two diseases and the associated economic impacts are fairly complex. For instance in areas where similar vectors transmit both human and animal trypanosomes, vector control interventions against tsetse are likely to reduce the burden of both human and animal disease. Similarly in East Africa where the parasite affects both humans and animals, many preventative and treatment interventions could bring benefits through reduced transmission to both humans and animals. However, in West Africa where *T.b. gambiense* infects only humans, trypanosome targeted interventions, such as case detection and treatment, are likely to bring benefits only to humans; interventions targeting the trypanosomiasis burden in livestock may provide benefits to humans only through improved agricultural productivity, and are unrelated to the burden of HAT, except where these interventions might have an effect on vectors that transmit the human parasite. More complicated to estimate or measure are the indirect costs which could be the result of long term changes in production systems or land use due to the presence or risk of trypanosomiasis in both animal and human populations (Shaw 2004) .

Several studies were identified that attempted to quantify the economic burden of African trypanosomiasis, or estimate returns to investment in the control of animal or human trypanosomiasis (Wilson et al 1986, Woudyalew et al 1999, Rowlands et al 1999, Blanc et al 1995, Shaw et al 1994, Brandl 1988b, Putt et al 1980). It is also estimated that across sub-Saharan Africa farmers spends upwards of USD 30 to 40 million a year on trypanocides to protect their livestock (Holmes et al 2004). Approximately 45-50 Million cattle are thought to live in zones of trypanosomiasis risk (Kristjanson et al 1999, Budd 1999); significant increases in numbers of adult cattle and in cattle ownership were observed after the rollout of tsetse control measures in Burkina Faso (Kamuanga et al 2001). In the late 1990s it was estimated that

improved trypanosomiasis control could return benefits of USD 700 million per year in Africa in terms of meat and milk productivity alone, and USD 1.3 billion if producer and consumer surpluses were considered (Kristjanson et al 1999); other studies estimated considerably higher increases in annual agricultural output of approximately USD 4.5 billion (Budd 1999, Swallow 2000).

Using interviews, one study estimated the direct and indirect costs to patients and their families to be a net loss of approximately 25% of the families' annual income per case (Gouteux et al 1987). Additional results from a study in the DRC reported that the median loss per HAT patient household on average was USD 249.94, which is approximately 43% of annual household revenue based on agricultural (Lutumba et al 2007), while in Tanzania USD 30.54 – 61.08 was the estimated total household loss (Reid 2012). Out-of-pocket expenses for patients and their families also contribute to economic burden for HAT. Matemba and colleagues (2010) found that on average USD 0.59 per night was required for relatives accompanying the patient to the hospital for treatment. Matemba and colleagues (2010) also found a return trip for treatment had a mean cost of USD 7.91, while meals were USD 17.70 per patient treated. Family members that had to pay for accommodation, on average spent USD 29.50 over the course of treatment. Out of pocket payments were also required for direct medical expenses including a screening treatment card (USD 0.46 - 0.57) (Robays 2008) or lab tests (USD 0.59) (Matemba 2010). Lastly, non-medical costs for hospital patients have been estimated to be USD 80.72 in rural Tanzania, including the costs associated with an accompanying person to the hospital/clinic (Matemba et al 2010).

4. Discussion

361 This paper reviews the literature on the costs associated with the prevention, treatment
362 and control of HAT. This information is important, as donors and control programs increase
363 funding and attention to strategies for eventual elimination. Importantly, this review lends insight
364 into the scarcity of literature on costs that if updated, could improve the efficiency of prevention
365 and control activities. In addition, this information is useful for collating cost information in a
366 common valuation system is also important for stakeholders interested in developing economic
367 evaluations to aid the decision making process.

368 There were few studies focused specifically on the costs related to health systems
369 research principles to the prevention, control, or treatment of HAT. This is likely due to the
370 limited focal nature of the disease, which complicates our general understanding of how HAT
371 control and treatment interaction complement one another. Though large swaths of the African
372 continent are theoretically at risk, in reality there are relatively few cases, which tend to be
373 concentrated in known foci. For this reason, potential health system interactions likely have
374 limited application at a national or regional scale.

375 It is likely that HAT deaths are greatly underreported (Odiit et al 2004). Underreporting
376 suggests that there is a gap in terms of how HAT control and treatment impact health information
377 systems. Improving disease surveillance and case detection is seen as one of the great challenges
378 to reducing morbidity and mortality due to HAT. While polyvalent screening teams might be
379 more efficient than the use of single purpose HAT active case detection (Shaw and Cattand
380 2001), the disease remains highly focal and thus investment in the use of integrated surveillance
381 is unlikely to impact health information system quality or coverage outside of the foci of HAT
382 transmission.

In addition, since HAT is invariably fatal if left untreated, all medicines required for HAT care must be considered essential for HAT endemic countries, and are listed as essential drugs by the WHO. As a neglected tropical disease, relatively little funding for new drug development is available globally, and the drugs for treatment of the disease are not marketed. These drugs (elfornithine, pentamidine and melarsoprol manufactured by Sanofi-Aventis, and suramin and nitrofurimox manufactured by Bayer Schering Pharma) are made available freely to the WHO by the manufactures.

We were unable to identify any studies examining the impacts of HAT programs on the availability and quality of human resources. Much of the control of HAT is based on vector control programs, which are typically vertically organized and run either in parallel or entirely outside of existing health system infrastructure. They thus pose a risk for diversion of human resources outside of the public health sector in some cases. Alternatively, surveillance strategies could be built on existing health management information systems (HMIS) or community based surveillance platforms potentially improving both, albeit in the limited areas of HAT foci.

Another gap relates to a paucity of cost information on how HAT control and treatment impacts service delivery. While the global impact of HAT treatment on service delivery is likely limited, the need for invasive and painful diagnostic measures (i.e. lumbar puncture) and dangerous treatments that require expensive monitoring over long periods of time suggests the potential for a serious burden on the health systems delivery of other services in areas with significant case-loads. Furthermore, there is documented evidence of increases in HAT transmission and risk in areas of conflict, both increasing the burden of disease in areas with major challenges for service delivery but also disproportionately increasing the need for improved service delivery (Berrang-Ford et al 2011).

Lastly, many of the studies identified lack standardization in terms of cost estimates, methods for presenting results, criteria for which costs are presented, and an overall accounting of all inputs as part of a treatment or control program. In addition, many of the vector control costs are quite old. This complicates the differentiation between financial and economic costs, which in turn creates challenges when making comparisons. In the context of increased attention to neglected tropical diseases in general, and HAT specifically, recent and standardized information on the costs for prevention, treatment and control interventions is needed.

5. Conclusion

The disease and disability resulting from HAT infection is enormous, which could negatively affect overall productivity of an individual and household. The results of this review show that recent and standardized information on the costs for prevention, treatment and control interventions is very scarce. While the literature available on costs provides useful information, most of the literature is outdated, focused on specific ecological contexts within countries, and is limited in terms of usefulness for developing estimates of the economic burden across Africa. The information presented herein should be updated to improve cost estimation. The collection of relevant and current cost data could play a meaningful role in funding and advocacy for resource mobilization for the control and elimination of HAT.

427

428

429 **Acknowledgments**

430 This research was supported by the Bill and Melinda Gates Foundation – through a Grant
431 awarded to the Swiss Tropical and Public Health Institute (grant number OPP1037660). The
432 opinions and assertions expressed herein are those of the authors and do not necessarily reflect
433 the official position or policy of Tulane University or the Swiss Tropical and Public Health
434 (Swiss TPH) Institute. The authors would like to express our gratitude to Dr. Peter Steinmann,
435 who provided a thorough review of the manuscript and suggested edits to improve the final text.

References

1. Abila, P. P., Okello-Onen, J., Okoth, J. O., Matete, G. O., Wamwiri, F., & Politzar, H. (2007). Evaluation of the cost-effectiveness of pyramidal, modified pyramidal and monoscreen traps for the control of the tsetse fly, *Glossina fuscipes fuscipes*, in Uganda. *Journal of Insect Science (Online)*. United States: National Livestock Resources Research Institute, Tororo, Uganda.
2. Agyemang K, Dwinger RH, Grieve AS, Bah ML. (1991). Milk-Production Characteristics and Productivity of Ndama Cattle Kept under Village Management in the Gambia. *Journal of Dairy Science* 74: 1599-1608.
3. Agyemang K, Dwinger RH, Jeannin P, Leperre P, Grieve AS, et al. (1990) Biological and Economic-Impact of Trypanosome Infections on Milk-Production in Ndama Cattle Managed under Village Conditions in the Gambia. *Animal Production* 50: 383-389.
4. Allsopp R, Hursey B. (2004). Insecticidal control of tsetse. In: Maudlin, I.,s, M. (Eds.), *The Trypanosomiasis*. CABI Publishing, Wallingford, pp. 491–507.
5. Barrett J. (1997). Economic issues in trypanosomiasis control. Chatham Maritime, UK: Natural Resources Institute.
6. Berrang-Ford L, Lundine J, Breau S. (2011). Conflict and human African trypanosomiasis. *Soc Sci Med* 72: 398-407.
7. Bill and Melinda Gates Foundation. Neglected Infectious Diseases: Strategy Overview. (n.d.). Retrieved May 13, 2015, from <http://www.gatesfoundation.org/What-We-Do/Global-Health/Neglected-Infectious-Diseases>
8. Blanc F, Le Gall F, Cuisance D. (1995). Control by traps of *Glossina fuscipes fuscipes* for protecting livestock in Central African Republic. V. Cost -benefit analysis of the programme. *Rev Elev Med Vet Pays Trop* 48.
9. Brandl F. (1988b). Farming and Resource Economics in the Tropica Vol 1. Economics of Trypanosomiasis Control in cattle. Keil, Germany
10. Brandl F. (1988a). Cost of different methods to control riverine tsetse in West Africa. *Tropical Animal Health and Production* 20: 67-77.
11. Brightwell R, Dransfield RD, Kyorku C. (1991). Development of a low-cost tsetse trap and odour baits for *Glossina pallidipes* and *G. longipennis* in Kenya. *Medical and Veterinary Entomology*. ENGLAND: International Centre of Insect Physiology and Ecology, Nairobi, Kenya.
12. Budd L. (1999). DFID-funded Tsetse and Trypanosome Research since 1980. Vol 2.: Economic analysis. Aylesford, Kent: Department for International Development (DFID).
13. Burri CBR. (2008). Human African Trypanosomiasis. Manson's Tropical Diseases. 22nd ed.
14. Cattand P, Jannin J, Lucas P. (2001). Sleeping sickness surveillance: an essential step towards elimination. *Trop Med Int Health* 6: 348-361.
15. Cattand P, Desjeux P, Guzman MG, Jannin J, Kroeger A, Medici A, Musgrove P, Nathan MB, Shaw A, Schofield C. Tropical Diseases Lacking Adequate Control Measures:

- Dengue, Leishmaniasis, and African Trypanosomiasis. In: Disease Control Priorities in Developing Countries, Chapter 23, p460.
16. Drugs for neglected tropical diseases initiatives (DNDi). ASTMH presentation 2014. http://www.dndi.org/images/stories/events2014/14astmh/Tarral_TreatmentsHAT_ASTMH_2014.pdf
 - Esterhuizen J, Rayaisse JB, Tirados I, Mpiana S, Solano P, et al. (2011) Improving the cost-effectiveness of visual devices for the control of riverine tsetse flies, the major vectors of human African trypanosomiasis. *PLoS Negl Trop Dis* 5: e1257.
 17. Evinson CK, KDS. (1982). A review of fixed-wing aerial spraying against *G. mortisans* in Zambia during the period 1968-1978. Lusaka, Zambia: Ministry of Agriculture and Water Development, Zambia
 18. Feldman U. (2004). The sterile insect technique as a component of area-wide integrated pest management of tsetse. In: Maudlin IHPMM, editor. *The Trypanosomiasis*. Cambridge, MA: CABI Publishing.
 19. Fevre EM, Wissmann BV, Welburn SC, Lutumba P. (2008). The burden of human African trypanosomiasis. *PLoS Negl Trop Dis* 2: e333.
 20. Franco JR, Simarro PP, Diarra A, Ruiz-Postigo JA, Jannin JG. (2014). The journey towards elimination of gambiense human African trypanosomiasis: not far, nor easy. *Parasitology* 141: 748-760.
 21. Gouteux JP, Bansimba P, Noireau F, Frezil JL. (1987). [Cost of the individual treatment of *Trypanosoma brucei* gambiense trypanosomiasis in a focus of infection in Niari (Congo)]. *Med Trop (Mars)* 47: 61-63.
 22. Holmes P. (2014). First WHO Meeting of Stakeholders on Elimination of Gambiense Human African Trypanosomiasis. *PLoS Negl Trop Dis* 8: e3244.
 23. Holmes PE MC, Geerts S. (2004). Current Chemotherapy of Animal Trypanosomiasis. In: Maudlin IHPMM, editor. *The Trypanosomiasis*. Cambridge, MA: CABI Publishing.
 24. Jemal A, Hughjones ME. (1995). Association of Tsetse Control with Health and Productivity of Cattle in the Didessa Valley, Western Ethiopia. *Prev Vet Med* 22: 29-40.
 25. Jemal A, Justic D, Hughjones ME. (1995). The Estimated Long-Term Impact of Tsetse Control on the Size of the Population of Cattle in the Didessa-Valley, Western Ethiopia. *Veterinary Research Communications* 19: 479-485.
 26. Kamuanga M, Sigue H, Swallow B, Bauer B, d'Ieteren G. (2001). Farmers' perceptions of the impacts of tsetse and trypanosomosis control on livestock production: evidence from southern Burkina Faso. *Trop Anim Health Prod* 33: 141-153.
 27. Kasper DB E, Fauchi A, Hauser S, Longo D, Jameson J, editor: McGraw-Hill. (2005). *Harrison's Principles of Internal Medicine*.
 28. Kristjanson PM, Swallow BM, Rowlands GJ, Kruska RL, de Leeuw PN. (1999) Measuring the costs of African animal trypanosomosis, the potential benefits of control and returns to research. *Agricultural Systems* 59: 79-98.

29. Lee CJ AM, Alsop NJ, Molyneux D, Roberts J, Putt N, Barlow F, Douthwaite RJ. (1982). The African trypanosomiasis: methods and concepts of control and eradication in relation to development. Centre for Overseas Pest Research.
30. Lutumba P, Meheus F, Robays J, Miaka C, Kande V, Buscher P, et al. (2007). Cost-effectiveness of Algorithms for Confirmation Test of Human African Trypanosomiasis. *Emerging Infectious Diseases*, 13(10), 1484–1490.
31. Lutumba P, Robays J, Miaka C, Kande V, Mumba D, Büscher P, Dujardin B, Boelaert M. (2006). Validity, cost and feasibility of the mAECT and CTC confirmation tests after diagnosis of African of sleeping sickness. *Trop Med Int Health* 11(4):470-8.
32. Lutumba P, Robays J, Miaka C, Kande V, Simarro PP, Shaw AP, Dujardin B, Boelaert M. (2005). [The efficiency of different detection strategies of human African trypanosomiasis by *T. b. gambiense*]. *Trop Med Int Health* 10(4):347-56.
33. Matemba LE, Fevre EM, Kibona SN, Picozzi K, Cleaveland S, et al. (2010) Quantifying the burden of rhodesiense sleeping sickness in Urambo District, Tanzania. *PLoS Negl Trop Dis* 4: e868.
34. McCord PF, Messina JP, Campbell DJ, Grady SC. (2012). Tsetse Fly Control in Kenya's Spatially and Temporally Dynamic Control Reservoirs: A Cost Analysis. *Appl Geogr* 34: 189-204.
35. Molyneux D, Ndung'u J, Maudlin I. (2010). Controlling sleeping sickness--"when will they ever learn?". *PLoS Negl Trop Dis* 4: e609.
36. Mullins G, Allsopp R, Nkori P, Kolyane M, Phillemon-Motsu TK. (1999). The effects of tsetse fly control on tourism in the Okavango Delta of Botswana. In ISCTRC publication No 119, 24th meeting, 1997, Maputo, Mozambique (pp. 555-562, Nairobi, Kenya: ISCTRC).
37. Odiit M, Shaw A, Welburn SC, Fevre EM, Coleman PG. (2004) Assessing the patterns of health-seeking behaviour and awareness among sleeping-sickness patients in eastern Uganda. *Ann Trop Med Parasitol* 98: 339-348.
38. Okoth, J. O. (1991). Description of a mono-screen trap for *Glossina fuscipes fuscipes* Newstead in Uganda. *Annals of Tropical Medicine and Parasitology*. ENGLAND: Uganda Trypanosomiasis Research Organization, Tororo.
39. Pepin J, Milord F. (1994). The treatment of human African trypanosomiasis. *Adv Parasitol* 33: 1-47.
40. Politi C, Carrin G, Evans D, Kuzoe FA, Cattand PD. (1995). Cost-effectiveness analysis of alternative treatments of African gambiense trypanosomiasis in Uganda. *Health Econ* 4: 273-287.
41. Putt SS, Matthewman RW, Bourn DM, Underwood M, James AD, Hallam MJ, Ellis PR. (1980) The Social and Economic Implications of Trypanosomiasis Control - a study of its impact on livestock production and rural development in northern Nigeria. Reading UK: Veterinary Epidemiology and Economics Research Unit, Reading University.

42. Reid H, Kibona S, Rodney A, McPherson B, Sindato C, Malele I, Vallely A. (2012). Assessment of the burden of human African trypanosomiasis by rapid participatory appraisal in three high-risk villages in Urambo District, Northwest Tanzania. *African Health Sciences*. Uganda: Australian Centre for International and Tropical Health, School of Population Health, University of Queensland, Herston, Brisbane, Australia.
43. Robays J, Raguenaud ME, Josenando T, Boelaert M. (2008). Eflornithine is a cost-effective alternative to melarsoprol for the treatment of second-stage human West African trypanosomiasis in Caxito, Angola. *Trop Med Int Health* 13: 265-271.
44. Rowlands GJ, Mulatu W, Leak SG, Nagda SM, d'Ieteren GD. (1999). Estimating the effects of tsetse control on livestock productivity--a case study in southwest Ethiopia. *Trop Anim Health Prod* 31: 279-294.
45. Shaw A. (2004). Economics of African Trypanosomiasis. In: Maudlin IHPMM, editor. The Trypanosomiasis. Cambridge, MA: CABI Publishing.
46. Shaw A, Munstermann S. (1994). Modelling the economic impacts of tsetse control using mono-pyramidal traps in Cote-d'Ivoire; Nairobi, Kenya. *The Kenya Veterinarian*.
47. Shaw AP, Cattand P. (2001). Analytical tools for planning cost-effective surveillance in Gambiense sleeping sickness. *Med Trop (Mars)* 61: 412-421.
48. Shaw AP. (1989.) Comparative analysis of the costs and benefits of alternative disease control strategies: vector control versus human case finding and treatment. *Ann Soc Belg Med Trop* 69 Suppl 1: 237-253.
49. Shaw AP, Torr S, Waisw, C, Robinson TP. (2007). Comparative costings of alternatives for dealing with tsetse: Estimates for Uganda. FAO Pro-Poor Livestock Policy Initiative Working Paper, no.40, Rome. Available at: <http://www.fao.org/ag/againfo/programmes/en/pplpi/docarc/wp40.pdf>
50. Shaw APM, Torr SJ, Waiswa C, Cecchi G, Wint GRW, Mattioli RC, Robinson TP. (2013). Estimating the costs of tsetse control options: an example for Uganda. *Preventive Veterinary Medicine*, 110(3-4), 290–303. doi:10.1016/j.prevetmed.2012.12.014
51. Simarro PP, Franco J, Diarra A, Postigo JA, Jannin J. (2012b). Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis. *Parasitology* 139(7):842-6.
52. Simarro, P. P., Cecchi, G., Franco, J. R., Paone, M., Diarra, A., Ruiz-Postigo, J. A., ... Jannin, J. G. (2012a). Estimating and mapping the population at risk of sleeping sickness. *PLoS Neglected Tropical Diseases*, 6(10), e1859. doi:10.1371/journal.pntd.0001859
53. Smith DH, Pepin J, Stich AHR. (1998). Human African trypanosomiasis: an emerging public health crisis. *Br Med Bull* 54: 341-355.
54. Steinmann P, Stone CM, Sutherland CS, Tanner M, Tediosi F. Contemporary and emerging strategies for eliminating human African trypanosomiasis due to *Trypanosoma brucei gambiense*: review. *Trop Med Int Health*. 2015 Jun;20(6):707-18. doi: 10.1111/tmi.12483. Epub 2015 Mar 12

55. Sutherland, C. S., Yukich, J., Goeree, R., & Tediosi, F. (2015). A Literature Review of Economic Evaluations for a Neglected Tropical Disease: Human African Trypanosomiasis ("Sleeping Sickness"). *PLoS Neglected Tropical Diseases*, 9(2), e0003397. doi:10.1371/journal.pntd.0003397
56. Swallow BM. (2000). Impacts of Trypanosomiasis on African agriculture. Rome: Food and Agriculture Association.
57. Torr SJ, Maudlin I, Vale GA. (2007). Less is more: restricted application of insecticide to cattle to improve the cost and efficacy of tsetse control. *Med Vet Entomol* 21: 53-64.
58. Vale GA, Torr SJ. (2005). User-friendly models of the costs and efficacy of tsetse control: application to sterilizing and insecticidal techniques. *Med Vet Entomol* 19: 293-305.
59. Wastling SL, Picozzi K, Kakembo ASL, Welburn SC. (2010). LAMP for human African trypanosomiasis: a comparative study of detection formats. *PLoS Neglected Tropical Diseases*, 4(11), e865
60. Welburn SC, Maudlin I, Simarro PP. (2009). Controlling sleeping sickness – a review. *Parasitology* 136: 1943-1949.
61. Wilson AJ, Gatuta GM, Njogu AR, Mgtutu SP, Alushula H. (1986). A Simple Epidemiologic Method for Animal Trypanosomiasis to Provide Relevant Data for Effective Financial Decision-Making. *Veterinary Parasitology* 20: 261-274.
62. Woudyalew Mulatu, Swallow BMR, GJ; Leak, SGA; D'Iteren, GDM; Ngada, SM (1999) Economic Benefits to framers of six years application of an insecticidal 'pour-on' to control tsetse in Ghibe, Southwest Ethiopia.: OAU/STRC.
63. World Health Organization (WHO). (1998). Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee. (1998). *World Health Organ Tech Rep Ser.* 1998; 881: I-VI, 1-114.
64. WHO. (2012). Accelerating Work to overcome the global impact of neglected tropical diseases: A roadmap for implementation. Retrieved September 05, 2014, from http://whqlibdoc.who.int/hq/2012/WHO_HTM_NTD_2012.1_eng.pdf.
65. World Health Organization (WHO). (2013). WHO Technical Report Series 984: Control and surveillance of human African trypanosomiasis. Retrieved January 14, 2014, from http://apps.who.int/iris/bitstream/10665/95732/1/9789241209847_eng.pdf
66. World Health Organization (WHO) (2014a). Human African Trypanosomiasis - First WHO stakeholders meeting on rhodesiense human African trypanosomiasis elimination. Retrieved May 2015, from http://www.who.int/trypanosomiasis_african/meeting_declaration_rhodesiense_2014/en/
67. World Health Organization (WHO) (2014b). Human African Trypanosomiasis - Symptoms Diagnosis and Treatment. Geneva: World Health Organization. Accessed December 2014: http://www.who.int/trypanosomiasis_african/diagnosis/en/

630 68. Zhang Y, MacArthur C, Mubila L, Baker S. (2010). Control of neglected tropical
631 diseases needs a long-term commitment. *BMC Med* 8, 67.

632

633

List of Figures

Figure 1: Incremental search results and final studies included

647 **List of Tables**

648 Table 1. Other vector control costs

649 Table 2: Cost for diagnostics and treatment for HAT

650 Table 3: Cost for case detection/surveillance strategies for *T.b. gambiense*

651

Table 1. Other vector control costs

Authors	Year	Description of cost	Cost
Sequential Aerial Techniques (SAT)			
Shaw	2007	Administration, supervision, and other indirect "non-field" costs	USD 36.37/km ² (14% of non-field costs)
		Entomological surveys, monitoring, feasibility studies	USD 223.10/km ²
		Aerial spraying- five cycles	USD 3,734.99/km ²
		Cost for creating a tsetse-free zone for isolated tsetse populations	USD 720.22/km ² & USD 608.67/km ²
Sterile Insect Technique (SIT)			
Vale & Torr	2005	Cost of rearing and sterilizing a male	USD 0.11
		Cost of release including accompaniment	USD 1.01/km ² /week
		Eradication Estimate	USD 42,033.91/insect population
Shaw	2007	Administration, supervision, and other indirect "non-field" costs	USD 56.99 km ² (19% of non-field costs)
		Entomological surveys, monitoring, feasibility studies	USD 235.22/km ²
		Capital items, fly rearing, fly release	USD 801.46/km ²
		Creating a tsetse-free zone for isolated tsetse populations: + SIT alone	USD 919.07/km ²
		Creating a tsetse-free zone for isolated tsetse populations: SIT + 90 day ITC	USD 1,228.26/km ²
		Creating a tsetse-free zone for isolated tsetse populations: SIT + 80% SAT	USD 1,228.26/km ²
Traps and Targets			
Shaw	1989	Total cost per trap (per person protected in 1 st year)	USD 24.50-27.76/ trap (USD 0.82/person)
		Total cost per screen (per person protected in 1 st year)	USD 6.53-13.07 per screen (USD 3-6.53/person)
Gouteux	1987	Cost per kit	USD 14.70
Brightwell	1991	Trap/odor bait system per unit	USD 12.96
Okoth	1991	Monoscreen - local	USD 1.86
		Monoscreen - imported materials	USD 1.92
		Biconical - local	USD 7.23
		Biconical - imported	USD 7.47
		Pyramidal Traps - local	USD 3.68

		Pyramidal Traps - imported	USD 3.87
Abila	2007	Pyramidal Traps cost per m	USD 4.50
		Modified pyramidal cost per m	USD 3.86
		Biconical & modified cost per m	USD 4.50
		Monoscreen cost per m	USD 2.89
Shaw	2007	Administration, supervision, and other indirect "non-field" costs	USD 36.37/km ² (14% of non-field costs)
		4 Traps/km ² (10 teams)	USD 213.40
		4 Traps/km ² (15 teams)	USD 277.66
		4 low cost Traps/km ² (10 teams)	USD 191.57
		4 low cost traps/km ² (15 teams)	USD 244.92
		8 Traps/km ² (20 teams)	USD 426.80
		8 Traps/km ² (30 teams)	USD 444.32
		10 Traps/km ² (25 teams)	USD 534.71
		10 Traps/km ² (38 teams)	USD 693.55
		20 Traps/km ² (50 teams)	USD 1,068.21
		20 Traps/km ² (75 teams)	USD 1,388.31
		Creating a tsetse-free zone for isolated tsetse populations: <i>G. fuscipes</i>	USD 1,115.50/km ²
		Creating a tsetse-free zone for isolated tsetse populations: Savannah tsetse	USD 602.61/km ²
		Creating a tsetse-free zone for isolated tsetse populations: Savannah tsetse	USD 491.06/km ²
		Creating a tsetse-free zone for isolated tsetse populations: Savannah tsetse species + local labor	USD 563.81/km ²
Shaw	2013	Average field cost per km ²	USD 561.25
		Average cost of field studies per km ²	USD 188.56
		Average cost of field deployment teams based on 10 teams	USD 15.53
		Cost of trap maintenance per annum per km ²	USD 61.67
Insecticide Treated Cattle (ITC)			
Vale & Torr	2005	Insecticide containing 20% α -cypermethrin purchased and shipped	USD 30.46 per liter
		Cost per animal	USD 0.002/animal/day
Torr et al	2007	Savings in insecticide: only treating the belly & legs of cattle	80 %

2007		Cost per animal whole-body regime	USD 2.22/animal/year
		Estimated cost per animal for restricted regime	USD 0.22/animal/year
Shaw	2007	Administration, supervision, and other indirect "non-field" costs	USD 36.67/km ² (14% of non-field costs)
		Entomological surveys, monitoring, feasibility studies	USD 223.10/km ²
		α -cypermethrin spray	USD 8.49 per animal per year
		α -cypermethrin spray, restricted application	USD 1.82 per animal per year
		Traditional pour-on (spot-on)	USD 27.28 per animal per year
		Creating a tsetse-free zone for isolated tsetse populations: pour (4/km ²)	USD 368.60/km ²
		Creating a tsetse-free zone for isolated tsetse populations: spray (4/km ²)	USD 293.42/km ²
		Creating a tsetse-free zone for isolated tsetse populations: pour-on (8/km ²)	USD 477.72/km ²
		Creating a tsetse-free zone for isolated tsetse populations: spray (8/km ²)	USD 327.37/km ²
		Creating a tsetse-free zone for isolated tsetse populations: restricted (8/km ² and fewer studies)	USD 162.47/km ²
		Creating a tsetse-free zone for isolated tsetse populations: spray	USD 215.82/km ²

Table 2: Cost for diagnostics and treatment for HAT

Authors	Year	Description	Cost (USD)
Diagnostics			
Lutumba	2006	Lymph node puncture (LNP)	USD
		FBE	USD
		TBF	USD
		CTC	USD
		mAECT	USD
Lutumba	2005	Cost per person screened	USD 2.23
WHO	1998	CATT test screen per person (one time)	USD 0.73
		CATT test screen per person (one time)	USD 0.44
		CATT test screen per person (one time)	USD 0.26
Wastling	2010	LAMP with Quant-IT Pico Green (per	USD 371.30
		LAMP with Turbidity (per 100	USD 0.001
		LAMP with hydroxynaphthol blue (per	USD 0.001
		LAMP with Calcein and MnCl ₂ (per 100	USD 0.001
Treatment			
Lutumba	2003	Pentamidine per vial	USD 2.05
Shaw & Gattand	2001	Pentamidine drug costs per treatment	USD 25.61
Shaw & Gattand	2001	Suramin drug costs per treatment	USD 41.79
Politi	1995	1 treatment of Elfofnithine	USD 285.06
Robays	2008	2 treatments of Elfofnithine	USD 334.31
Simarro	2012	Average total cost of Elfofnithine administration	USD 745.08
Simarro	2012	NECT 4 treatments	USD 1,550.74
Simarro	2012	NECT 1 treatment	USD 387.68
Lutumba	2003	Melarsoprol per vial	USD 7.06
Lutumba	2007	Melarsoprol treatment	USD 144.10
Politi	1995	Melarsoprol treatment per patient	USD 66.99
Robays	2008	Melarsoprol-Prednisolone treatment per	USD 75.52

Table 3: Cost for case detection/surveillance strategies for *T.b. gambiense* HAT

Authors	Year	Description of cost	Cost (USD)
Shaw	1989	Surveillance at health center	USD 2.20 per person tested (USD 0.62 per population)
		Road blocks near health centers	USD 1.34 per person tested (USD 0.13 per population)
		Multipurpose mobile team	USD 1.25 per person tested (USD 0.16 per population)
		Single-purpose mobile team	USD 1.71 per person tested (USD 0.85per population)
		Cost per serological test	USD 1.58
		Cost per parasitological exam	USD 2.53
Shaw & Cattand	2001	Rural health centers and mobile teams (0.05%)	USD 2,696.15 per patient found
		Rural health centers and mobile teams (1%)	USD 161.77-188.73per patient found
		Rural health centers and mobile teams (1%-5%)	Approximately USD 40.44 per patient found
		Rural health centers and mobile teams (20%)	Approximately USD 13.48
		Rural health centers and mobile teams (50%)	Approximately USD 6.74
		Community health workers (0.05%)	Just under USD 2,700 per patient found
		Community health workers (1%)	Less than USD 134.81 per patient found
		Community health workers (1% -5%)	USD 29.66 per patient found
		Community health workers (20%)	Approximately USD 13.48 per patient found
		Community health workers (50%)	Approximately USD 6.74 per patient found
		Passive or fixed detection posts (0.05%)	USD 67.40 per patient found
		Passive or fixed detection posts (1%)	USD 26.96 per patient found
		Passive or fixed detection posts (1%-5%)	USD 18.87 per patient found
		Passive or fixed detection posts (20%)	Approx. USD 13.48 per patient found
		Passive or fixed detection posts (50%)	Approx. USD 13.48 per patient found
		Initial screening and parasitological exams	USD 3.37-4.72 per person
Lutumba et al	2007	Annual costs for operations of mobile teams	
		Vehicles	USD 7,212.62
		Medical and lab supply (includes CATT reagents)	USD 3,884.26
		Training	USD 945.25
		Personnel	USD 16,212.57
		Medical and lab supply	USD 20,826.57
		Essential drugs (not for HAT)	USD 2,955.42

		Vehicle operation & maintenance	USD 7,318.18
--	--	---------------------------------	--------------

Graphical Abstract

Human African trypanosomiasis prevention, treatment and control costs: A systematic review.
Keating J, Yukich JO, Sutherland CS, Woods G, Tediosi F